Who and Where
Who is looking at NAC in COVID?
Determination of efficacy of N-Acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
CHA-IRB-1139-05/20
ClinicalTrials.gov ID NCT04419025
THIS STUDY HAS CONCLUDED ENROLLMENT
Phase
Application submission to CHA IRB May 1, 2020
Approval August 7, 2020
Enrollment September 30, 2020
Enrollment Halted May 14, 2021
Principal Investigator (PI)
Melisa Lai-Becker MD
Enrollment Eligibility
Age >= 18 years, not pregnant at time of enrollment; known or suspect COVID-19 disease AND one or more of any influenza-like symptom, including:
diarrhea
vomiting
fever (subjective or measured)
chills
myalgias
fatigue
sore throat
headache
cough
nasal/sinus congestion or rhinorrhea
shortness of breath
chest pain
John Adams MD MPH Internist and Pediatrician, CHA Acute Care/Respiratory Clinic project leader; Instructor, Harvard Medical School
Kerry Blomquist RN Emergency Nurse, CHA Everett Hospital
Pieter Cohen MD Internist, Primary Care, CHA; Associate Professor, Harvard Medical School
Julie Devito PA-C Physician Assistant, CHA Department of Emergency Medicine
Jessica Early MD Family Medicine Physician, Hospitalist, CHA; Assistant Professor, Tufts University School of Medicine
Ellie Grossman MD MPH Primary Care Lead for Behavioral Health Integration; Instructor, Harvard Medical School
Lara Hall MD Family Medicine Physician - Urgent Care, Kaiser Permanente (Oregon)
Rachel Hathaway MD Hospital Medicine Physician. Director, HMS Medicine Sub Internship; Director, CHA Internal Medicine Resident Evaluation; Instructor, Harvard Medical School
Janice N. John PA-C MHS MHCDS Medical Director, CHA Acute Care/Respiratory Clinic; Chief PA, Primary Care; Associate Medical Director, Assembly Square Primary Care
Duncan Kuhn MD Pulmonary & Critical Care Physician, CHA; Pulmonary & Critical Care Physician, North Shore Medical Center (Salem MA); Infectious Diseases specialist; Instructor, Harvard Medical School
Melisa Lai-Becker MD Chief, Everett Emergency Department; Director, Division of Medical Toxicology; Medical Toxicologist, Regional Center for Poison Control and Prevention Serving MA & RI; Medical Toxicologist, Boston Children's Hospital; Assistant Professor, Harvard Medical School
Anna Rabkina MD Family physician, Primary Care, CHA, Instructor, Harvard Medical School
Mary Regan PharmD Director, Clinical and Academic Pharmacy Services; Senior Clinical Pharmacist Specialist – Critical Care; Administrator, ACPE-Accredited CPE Programming
Neha Sandeep PA-C Family Medicine PA, CHA Acute Care/Respiratory Clinic and Primary Care, CHA
Yamini Saravanan MD MHS Clerkship Director, HMS Primary Care; Clerkship Director, HMS Internal Medicine Clerkship; Associate Director, HMS Primary Care Experience; Instructor, Harvard Medical School
Alix Schrager MD Internist, Primary Care, Massachusetts General Hospital (MGH); Instructor in Medicine, Harvard Medical School
Anna Shapiro PA-C Physician Assistant, CHA Primary Care
Linda Shipton MD Infectious Diseases specialist, CHA and Spaulding Rehabilitation Center; Medical Director, Tuberculosis Program, MA DPH, CHA; Assistant Professor, Harvard Medical School
Tom Seufert MD Emergency Physician; Associate Director of Clinical Informatics; Director of Emergency Informatics; Instructor, Harvard Medical School
Lisa Yasi RRT Respiratory Therapist, CHA Everett
Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19
ClinicalTrials.gov Identifier: NCT04545008
Prisma Health and Clemson University
A Study of N-acetylcysteine in Patients With COVID-19 Infection
ClinicalTrials.gov Identifier: NCT04374461
Memorial Sloan Kettering Cancer Center
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)
ClinicalTrials.gov Identifier: NCT04458298
Ashvattha Therapeutics (formerly Orpheris, Inc.)
Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)
ClinicalTrials.gov Identifier: NCT04455243
King Saud University, Saudi Arabia
Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)
ClinicalTrials.gov Identifier: NCT04370288
Mashhad University of Medical Sciences, Iran
Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
ClinicalTrials.gov Identifier: NCT04279197
ShuGuang Hospital, Shanghai, China
Antioxidant Therapy for COVID-19 Study (GSHSOD-COVID)
ClinicalTrials.gov Identifier: NCT04466657
Obafemi Awolowo University, Nigeria